Patents Assigned to Novartis
  • Publication number: 20120237536
    Abstract: Influenza, pneumococcus and/or RSV vaccines are administered as a combination vaccine while retaining immunogenic efficacy. This combination simplifies immunisation against these two lower respiratory tract infections. The pneumococcal vaccine ideally includes at least one pneumococcal polypeptide.
    Type: Application
    Filed: September 10, 2010
    Publication date: September 20, 2012
    Applicant: NOVARTIS
    Inventors: Rino Rappuoli, Ralf Leo Clemens
  • Patent number: 7465723
    Abstract: The present invention relates to the use of carbamazepine derivatives in treating tinnitus.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: December 16, 2008
    Assignee: Novartis
    Inventor: Markus Schmutz
  • Publication number: 20080139559
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 12, 2008
    Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS
    Inventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
  • Patent number: 6980842
    Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: December 27, 2005
    Assignee: Novartis
    Inventors: Wayne Front March, Mary Flowers Mowery-McKee
  • Patent number: 6900367
    Abstract: Transgenic flies displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: May 31, 2005
    Assignee: Novartis
    Inventors: Dalia Cohen, Uwe Jochen Dengler, Alyce Lynn Finelli, Felix Freuler, Mary Konsolaki, Mischa Werner Henri Marie Reinhardt, Susan Zusman
  • Patent number: 6833241
    Abstract: The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 21, 2004
    Assignee: Novartis
    Inventors: Mark A. Labow, Craig Stephen Mickanin, Umesh Bhatia